NCT04807114View on ClinicalTrials.gov

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

RecruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Lung Diseases, InterstitialNSCLCImmunotherapy
Interventions
DRUG

Immune checkpoint inhibitor

Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \> 50%)

DRUG

Chemotherapy + Immune checkpoint inhibitor

Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)

Trial Locations (1)

3000

RECRUITING

Universitaire Ziekenhuizen Leuven, Leuven

All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER